PharmaTher Holdings Ltd (TSE:PHRM) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PharmaTher Holdings Ltd. announced they have canceled a planned meeting with the FDA after receiving satisfactory preliminary responses regarding their Ketamine product’s application. The company is addressing minor deficiencies noted by the FDA and plans to resubmit necessary information by January 2025.
For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.